Does Medicaid cover GLP-1 medications?
medicaid
Medicaid is the federal-state health insurance program for low-income individuals; coverage varies significantly by state.
What Medicaid specifically requires
- KFF: 13 state Medicaid programs covered GLP-1s for obesity in fee-for-service as of January 2026, down from 16 in October 2025. California, New Hampshire, Pennsylvania and South Carolina ended coverage. KFF: Medicaid coverage of and spending on GLP-1s, Jan 16, 2026
- North Carolina ended Medicaid GLP-1 obesity coverage in October 2025 and reinstated it in December 2025. KFF: Medicaid coverage of and spending on GLP-1s, Jan 16, 2026
- MassHealth ended coverage of drugs used for weight loss, including Wegovy, Zepbound and Saxenda, on July 3, 2026. Coverage continues with prior authorization for cardiovascular disease, MASH and sleep apnea. MassHealth Pharmacy Facts #271: anti-obesity medications, Mar 12, 2026
- California Medi-Cal removed Wegovy, Zepbound and Saxenda from its drug list for weight loss on January 1, 2026; members under 21 are reviewed under EPSDT. Anthem Blue Cross (Medi-Cal): GLP-1 Coverage Considerations, Nov 14, 2025
- CMS announced the BALANCE model in December 2025, a voluntary program to negotiate lower GLP-1 prices for Medicaid and Medicare. KFF: Medicaid coverage of and spending on GLP-1s, Jan 16, 2026
Medicaid coverage by drug
- Varies by planWegovysemaglutide
Each state decides. KFF counted 13 state Medicaid programs covering GLP-1s for obesity in January 2026, down from 16 in October 2025; Massachusetts then ended coverage on July 3, 2026, leaving 12 or fewer as of July 2026. Check your state's preferred drug list.
- Varies by planZepboundtirzepatide
Zepbound follows each state's rules for weight-loss drugs. California Medi-Cal removed Zepbound from its drug list for weight loss on January 1, 2026, and MassHealth ended weight-loss coverage on July 3, 2026. Both still consider Zepbound for sleep apnea.
- CoveredOzempicsemaglutide
MassHealth lists Ozempic as a preferred GLP-1 for diabetes, and California Medi-Cal keeps Ozempic on its drug list restricted to type 2 diabetes. Neither covers it for weight loss.
- CoveredMounjarotirzepatide
MassHealth lists Mounjaro as a preferred GIP/GLP-1 drug for diabetes, and California Medi-Cal keeps Mounjaro on its drug list restricted to type 2 diabetes. Neither covers it for weight loss.
- Varies by planSaxendaliraglutide
California Medi-Cal removed Saxenda from its drug list for weight loss on January 1, 2026, and MassHealth ended coverage of Saxenda for weight loss on July 3, 2026. Other states set their own rules.
- CoveredZoloftsertraline
State Medicaid programs cover generic sertraline. Check your state's preferred drug list.
- CoveredLexaproescitalopram
State Medicaid programs cover generic escitalopram. Check your state's preferred drug list.
- Varies by planViagrasildenafil
Federal law lets state Medicaid programs exclude drugs used for sexual or erectile dysfunction unless they are used for another FDA-approved condition (42 U.S.C. 1396r-8(d)(2)(H)). Sildenafil for pulmonary arterial hypertension is a separate approved use. Check your state's drug list.
- Varies by planCialistadalafil
State Medicaid programs may exclude tadalafil for erectile dysfunction (42 U.S.C. 1396r-8(d)(2)(H)), but the exclusion does not reach its FDA-approved use for benign prostatic hyperplasia. Check your state's drug list.
- Limited coveragePropeciafinasteride
Federal law lets state Medicaid programs exclude drugs used for cosmetic purposes or hair growth (42 U.S.C. 1396r-8(d)(2)(C)), which covers finasteride 1 mg for hair loss. Finasteride 5 mg for BPH is a different use.
Reminder: coverage varies by plan
Medicaid offers many plan designs. The same medication can be covered under one Medicaid plan and excluded from another. Always confirm with your specific plan's formulary or call the number on your insurance card before assuming coverage.
Frequently asked
Does Medicaid cover GLP-1 medications for weight loss?+
Each state decides whether Medicaid covers GLP-1s for weight loss. KFF counted 13 state programs covering them for obesity in January 2026, down from 16 in October 2025; Massachusetts then ended its coverage on July 3, 2026, leaving 12 or fewer as of July 2026. When covered, these drugs are typically subject to prior authorization. GLP-1 coverage at Medicaid varies plan by plan. For Wegovy and Zepbound (weight-loss indications), expect prior authorization at minimum, with formal documentation of BMI and previous lifestyle interventions. For Ozempic and Mounjaro (type 2 diabetes), coverage is generally easier when prescribed for diabetes.
Does Medicaid require a prior authorization for Wegovy or Zepbound?+
Yes, prior authorization (PA) is the norm for weight-loss GLP-1s across Medicaid plans. A PA typically requires documented BMI ≥30 (or ≥27 with a comorbidity), prior attempts at structured weight loss, and sometimes step-therapy through cheaper alternatives. Your prescriber's office files the PA.
How do I check if my specific Medicaid plan covers a drug?+
Three steps: (1) Log into your Medicaid member portal and search the drug formulary by name. (2) Call the member services number on your insurance card. (3) Ask your prescriber to submit a benefits inquiry. Plan designs differ widely within Medicaid — what's covered for one member may not be covered for another.
What if Medicaid denies my GLP-1 prior authorization?+
Three options: (1) Appeal — most plans grant an appeal that adds physician peer-to-peer review; your prescriber can request this. (2) Switch indication if clinically appropriate (e.g., if you have prediabetes and BMI ≥30, your physician may have different coverage paths). (3) Use manufacturer direct-pay (NovoCare, LillyDirect) which doesn't depend on insurance approval. Federal program coverage policies follow CMS rules and have less plan-by-plan variability — appeals are still available.
Are compounded GLP-1s covered by Medicaid?+
Generally no. Most insurance plans, including Medicaid, do not cover compounded semaglutide or tirzepatide regardless of pharmacy. As of 2026, the FDA is winding down large-scale compounding, so coverage questions are increasingly moot — most patients are transitioning to branded GLP-1s or manufacturer direct-pay programs.